ANN ARBOR, Mich., Sept. 19 /PRNewswire/ -- QuatRx Pharmaceuticals, a biopharmaceutical company focused on research and development of therapeutic compounds for the treatment of major endocrine, metabolic and cardiovascular diseases, today announced the appointment of Rochelle Hanley, M.D., as chief medical officer. Dr. Hanley will oversee clinical development of QuatRx’s product pipeline. Prior to joining QuatRx, Dr. Hanley was vice president, clinical R&D site head of Pfizer’s Michigan Laboratories, where she oversaw the clinical operations of Pfizer’s Michigan research and development facility. Dr. Hanley has extensive experience managing clinical development, especially in metabolic disorders and cardiovascular disease. In her career, Dr. Hanley has also held clinical development management roles at both Glaxo Wellcome and Parke-Davis Pharmaceutical Research.
